silvr_surfr
2 minutes ago
Brusselsspirit, I agree it is a house of cards what with buying Novitium to bring in-house drug development capability and then shortly thereafter proclaiming to be a rare disease company too and then merging with Alimera. All the while, having a hodgepodge of legacy opportunities with Libigel, Pil